Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Galapagos NV - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GLPG
Nasdaq
8731
https://www.glpg.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Galapagos NV - ADR
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
- Apr 4th, 2024 8:01 pm
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
- Apr 3rd, 2024 1:35 pm
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
- Mar 28th, 2024 8:01 pm
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
- Mar 26th, 2024 8:01 pm
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
- Mar 18th, 2024 1:35 pm
11 Oversold Biotech Stocks To Buy Right Now
- Mar 17th, 2024 9:20 pm
Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript
- Feb 24th, 2024 1:30 pm
Galapagos announces full year 2023 results and outlook for 2024
- Feb 22nd, 2024 9:01 pm
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
- Feb 22nd, 2024 9:01 pm
Galapagos presents at EBMT-EHA annual meeting 2024
- Feb 15th, 2024 9:01 pm
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
- Jan 31st, 2024 9:01 pm
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
- Jan 4th, 2024 9:01 pm
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
- Jan 3rd, 2024 11:01 pm
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
- Jan 3rd, 2024 9:01 pm
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
- Jan 3rd, 2024 9:01 pm
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
- Jan 2nd, 2024 6:00 am
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
- Dec 19th, 2023 9:01 pm
Best Momentum Stocks to Buy for December 13th
- Dec 13th, 2023 3:00 pm
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
- Dec 9th, 2023 5:00 pm
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
- Dec 7th, 2023 9:01 pm
Scroll